Skip to main content
NMRA logo

NMRA · Neumora Therapeutics, Inc.

Track NMRA — free
$0.33 -0.01 (-3.78%) At close · Nov 20
Market Cap
$63.01M
Shares
188.69M
Volume · Nov 20 1.06M Avg daily vol (3M) 1.67M

Price & Indicators

 

Key stats

Close
$0.33
Fri 20 Nov
Open
$0.34
Fri 20 Nov
Average volume, 30 days
1.8M
shares a session
Short interest
7.0M
3.7% of shares · 5.1 days to cover
Day range
$0.30$0.36
Open $0.34 Close $0.33
52-week closing range
$0.33$3.59
Close $0.33 90.7% under the high
Short volume, last session
73%
Last earnings
Mar 30, 2026
Latest filing
10-Q · Nov 16
Price history
Sep 2023 to Nov 2026

Latest documents

2026
Nov 16
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Going concern uncertainty as losses and cash burn persist

Neumora reported a nine-month net loss of $131.0 million and $85.7 million in cash and cash equivalents as of September 30, 2026, raising substantial doubt about its ability to continue as a going concern within one year of filing.

Net loss $34.44M Diluted EPS -$0.18
Read from the MD&A section
4 source passages
Neumora is developing NMRA-215, a highly brain-penetrant, oral NLRP3 inhibitor for the treatment of obesity and cardiovascular risk. As of September 30, 2026, we had $85.7 million of cash and cash equivalents. Net cash used in operating activities for the nine months ended September 30, 2026 was $119.4 million, primarily reflecting our net loss of $131.0 million partially offset by noncash charges of $22.1 million. Given our recurring losses from operations and negative cash flows, and based on our current operating plan, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year from the date of filing of this Form 10-Q. Open the document at this passage
Nov 16
Current report 8-K
NMRA-215 IND submitted to U.S. Food and Drug Administration

Neumora Therapeutics submitted an IND for NMRA-215 to the U.S. Food and Drug Administration, reported $85.7 million cash as of September 30, 2026 and a third-quarter net loss of $34.4 million, and is not providing updated financial runway guidance.

Financial results
5 source passages
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update. Neumora is developing NMRA-215, a potentially best-in-class, highly brain-penetrant oral NLRP3 inhibitor, for the treatment of obesity and cardiometabolic disease and has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration. Cash Position: As of September 30, 2026, Neumora had cash and cash equivalents of $85.7 million. Net Loss: The Company reported a net loss of $34.4 million for the third quarter of 2026, as compared to $56.8 million for the same period in 2025. Financial Guidance: Neumora is not providing updated financial runway guidance. Open the document at this passage
Oct 30
Current report 8-K Events of Oct 26
Nasdaq Notice on Minimum Bid Price; 180 Days to Regain Compliance

Neumora received written notice from Nasdaq on October 26, 2026 that its common stock is below the $1.00 minimum bid price for continued listing. It has until April 26, 2027 to regain compliance, which requires a closing bid of at least $1.00 for ten consecutive business days.

Delisting notice or listing transfer
3 source passages
On October 26, 2026, Neumora Therapeutics, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until April 26, 2027, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$190.43M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$27.65M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+16.1%
Year over year · more shares
Price change (1Y)
-85.9%
Trailing year
Short interest
3.7%
Latest settlement · 5.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −80%
below
Price vs 50-day avg −35%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −12%
trailing
6-month return −81%
trailing
YTD return −81%
this year
Relative strength −72%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+10% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.71% of shares out · ▲ +24.2% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
128 holders — mid 3-yr range
Squeeze score 54
elevated · 0–100
Fundamentals
Fair
EPS growth +5%
Y/Y
Free cash flow $-206.6M
Balance sheet $68.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 132%
annualized · 1-yr
Max drawdown −91%
past year
ATR 20.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−80% Bearish
Price vs 50-day avg
−35% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+10% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.71% of shares out · ▲ +24.2% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
128 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $4
vs 200-day avg -80% vs 50-day avg -35%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NMRA
Neumora Therapeutics, Inc.
this stock
$63.01M -81.3% — — 3.7%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
128
% held
62.0%
Net QoQ
+36.6M sh
Top holder
ARCH Venture Management,…
Held Float
View
Held by Funds
Fund positions
94
View
Short & Settlement
Short Interest Rising
Shares short
7.0M
Days to cover
5.1d
Change
+1.4M sh
View
Short Volume
Short vol %
73%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
88.9K
Value
$38.2K
As of
Oct 16, 2026
View
Off-Exchange
Off-exchange %
61.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-236.9M
EPS diluted
$-1.45
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 16, 2026
This year
21

Neumora reported a nine-month net loss of $131.0 million and $85.7 million in cash and cash equivalents as of September 30, 2026, raising substantial doubt about its ability to continue as a going concern within one year of filing.

View
Proposed Sales
Value
$66.4K
Shares
41.6K
Filed
Aug 21, 2026
View
Exempt Offerings
Offering
$474.4M
Filed
Jan 3, 2023
View
Earnings & Events
Webcasts
Last webcast
May 27, 2026
View
Investor Relations
Latest news
Neumora Therapeutics Reports Thir…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
NMRA -22.2% -12.0% -80.9% -9.1% -81.4%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -13.6% -2.8% -71.7% -0.4% -82.5%
Key facts CIK 1885522 CUSIP 640979100 13F (30d) 143 filings 117 filers Visit website Investor relations